Clinical Trials on High Risk Polycythemia Vera
Total 808 results
-
Ronald HoffmanNational Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...CompletedHigh Risk Polycythemia Vera | High Risk Essential ThrombocythemiaUnited States, Italy, United Kingdom, France
-
Ronald HoffmanNational Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...CompletedHigh Risk Polycythemia Vera | High Risk Essential ThrombocythemiaUnited States, Italy
-
Northwestern UniversityNational Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma SocietyWithdrawnPrimary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis PhaseUnited States
-
Array BioPharmaCompletedAML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDSUnited States, Australia, Italy, Spain, France, Switzerland, United Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnPrimary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential ThrombocythemiaUnited States
-
Ronald HoffmanNovartisUnknownPrimary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-Essential Thrombocythemia Related MyelofibrosisUnited States
-
M.D. Anderson Cancer CenterRecruitingPrimary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential ThrombocythemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Novartis PharmaceuticalsCompletedPrimary Myelofibrosis | Secondary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis PhaseUnited States
-
John MascarenhasTerminatedPrimary Myelofibrosis | Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-essential Thrombocythemia Related MyelofibrosisUnited States
-
PharmaEssentia Japan K.K.RecruitingPolycythemia Vera (PV)Japan
-
Novartis PharmaceuticalsCompletedPolycythemia Vera (PV)United States
-
AstraZenecaUniversity of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...CompletedPrimary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia MyelofibrosisUnited States, France
-
PharmaEssentia Japan K.K.Recruiting
-
PharmaEssentia Japan K.K.CompletedPolycythemia Vera (PV)Japan
-
Memorial Sloan Kettering Cancer CenterEli Lilly and Company; Incyte CorporationRecruitingMyelofibrosis Due to and Following Polycythemia VeraUnited States
-
Ionis Pharmaceuticals, Inc.RecruitingPhlebotomy Dependent Polycythemia VeraUnited States, Canada, Hungary, United Kingdom, Australia, Poland
-
Novartis PharmaceuticalsTerminatedPrimary Myelofibrosis | Post-Polycythemia Vera | Post-Essential ThrombocytopeniaUnited States
-
CelgeneRecruitingPrimary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera MyelofibrosisFrance, Belgium, Austria, Spain, Australia, Canada, Japan, United States, Korea, Republic of, Romania, Israel, Italy, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Colombia, Argentina, Chile and more
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPrimary Myelofibrosis | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential ThrombocythemiaUnited States
-
University Hospital, BrestRecruitingPolycythemia Vera | Essential Thrombocythemia | High-risk Patients | Prefibrotic/Early Primary Myelofibrosis | JAK2 V617FFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedPrimary Myelofibrosis | Splenomegaly | Hepatomegaly | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential ThrombocythemiaUnited States
-
CelgeneImpact Biomedicines, Inc., a wholly owned subsidiary of Celgene CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post-Polycythemia VeraAustralia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
-
Gruppo Italiano Malattie EMatologiche dell'AdultoNot yet recruitingPolycythemia Vera
-
Perseus Proteomics Inc.Recruiting
-
Protagonist Therapeutics, Inc.CompletedPolycythemia VeraKorea, Republic of, Malaysia
-
Protagonist Therapeutics, Inc.Active, not recruiting
-
ItalfarmacoCompletedPolycythemia VeraItaly
-
Novartis PharmaceuticalsCompletedPolycythemia VeraGermany, Belgium, France, Austria, Canada, Thailand, Norway, Bulgaria, Portugal, Chile, Mexico, Sweden
-
Weill Medical College of Cornell UniversityBristol-Myers SquibbTerminated
-
ExelixisTerminated
-
Weill Medical College of Cornell UniversityCompleted
-
Sierra Oncology LLC - a GSK companyCompletedPrimary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia MyelofibrosisUnited States, France, Canada, Germany, Australia
-
Sierra Oncology, Inc.CompletedPrimary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia MyelofibrosisUnited States, Canada, Australia
-
RWTH Aachen UniversityNovartis PharmaceuticalsActive, not recruitingPolycythemia Vera (PV) | Essential Thrombocythemia (ET)Germany
-
Bristol-Myers SquibbRecruitingPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisKorea, Republic of
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisItaly
-
NS Pharma, Inc.Nippon Shinyaku Co., Ltd.RecruitingPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States, Korea, Republic of, Malaysia, Italy, Germany, Poland, United Kingdom, Thailand, Turkey
-
CelgeneImpact Biomedicines, Inc., a wholly owned subsidiary of Celgene CorporationCompletedPrimary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States, Canada
-
Novartis PharmaceuticalsCompletedPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisGermany
-
Novartis PharmaceuticalsCompletedIdiopathic Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia-Vera MyelofibrosisUnited Kingdom, Ireland, Germany, Italy, France
-
Incyte CorporationCompletedPrimary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia MyelofibrosisUnited States
-
ItalfarmacoRecruitingPolycythemia VeraUnited States
-
Institute of Hematology & Blood Diseases HospitalRecruiting
-
Novartis PharmaceuticalsRecruiting
-
Silence Therapeutics plcRecruitingPolycythemia VeraUnited States, Australia, Malaysia, Bulgaria, Poland
-
PharmaEssentiaRecruitingPolycythemia VeraUnited States, Canada
-
Protagonist Therapeutics, Inc.RecruitingPolycythemia VeraUnited States, Hong Kong, Israel, Canada, Spain, Australia, Austria, Germany, United Kingdom, Hungary, Netherlands, Czechia, Portugal, Italy, Poland, France, Belgium, Chile, Turkey, Mexico
-
University of BirminghamNovartis; National Cancer Institute, France; MPN VoiceRecruitingPolycythemia VeraUnited Kingdom
-
Imago BioSciences, Inc., a subsidiary of Merck...Active, not recruitingPolycythemia VeraUnited States, Australia, United Kingdom
-
PharmaEssentiaActive, not recruiting